News
LJUIF
0.540
NaN%
--
SSY Group Wins Strong Shareholder Backing at 2026 AGM
TipRanks · 2d ago
SSY Group Wins Trio of NMPA Approvals, Expanding China Drug Portfolio
TipRanks · 6d ago
SSY Group Wins NMPA Approval for New Vitamin B12 Injection Specification
TipRanks · 05/07 08:40
SSY Group Wins Hebei Approval for New Inflammation and Cardiovascular Diagnostic Test Kits
TipRanks · 05/06 09:11
SSY Group Wins Key China Drug Approvals, Expands Chronic and Pediatric Portfolio
TipRanks · 05/06 04:07
SSY Group posts higher Q1 2026 revenue amid margin pressure
TipRanks · 05/04 08:38
SSY Group Wins Chinese Approvals for Two Cardiovascular Injectables
TipRanks · 04/27 04:07
SSY Group Sets 2026 AGM to Approve Results, Dividend and Share Issuance Mandate
TipRanks · 04/21 09:10
SSY Group Wins China Approval for Furosemide Bulk Drug
TipRanks · 04/21 08:38
SSY Group Wins NMPA Approvals for New Electrolyte and Antiemetic Injections
TipRanks · 04/10 04:14
Citi Remains a Buy on SSY Group (LJUIF)
TipRanks · 04/09 00:29
SSY Group (LJUIF) Gets a Buy from CICC
TipRanks · 04/03 05:28
SSY Group (LJUIF) Receives a Buy from Huatai Securities
TipRanks · 03/31 05:27
SSY Group Wins China Approval for Upadacitinib Bulk Drug
TipRanks · 03/31 01:36
SSY Group Wins China Approval for New Irrigation and Bumetanide Injectables
TipRanks · 03/27 11:43
SSY Group FY25 Profit Drops On Weak Revenues; Cuts Dividend- Update
NASDAQ · 03/27 05:59
SSY Group Profit Halves as Revenue and Margins Slide in Challenging 2025
TipRanks · 03/27 04:10
SSY Group Declares Final Cash Dividend of HKD 0.03 per Share for 2025
TipRanks · 03/27 04:08
SSY Group Wins First PRC Approval for New Fat-Soluble Vitamin Injection
TipRanks · 03/13 09:16
SSY Group Wins China Approval for Homegrown High-Performance Infusion Tubing
TipRanks · 03/13 08:43
More
Webull provides a variety of real-time LJUIF stock news. You can receive the latest news about Ssy Group through multiple platforms. This information may help you make smarter investment decisions.
About LJUIF
SSY Group Ltd, formerly known as Lijun International Pharmaceutical Holding Co Ltd, is an investment holding company principally engaged in the research, development, manufacture and sale of pharmaceutical products. The Company’s main products include finished medicines of mainly intravenous infusion solution to hospitals and distributors, bulk pharmaceuticals and medical materials. The Company’s products mainly include non-PVC (Polyvinyl chloride) soft bag infusion solution, PP (Polypropylene) plastic bottle infusion solution and Glass bottle infusion solution. The Company’s products also include Hydrochloride Betahistine, Hydrochloride Ambroxol and Doxofylline as well as bulk pharmaceuticals including caffeine, theophylline, aminophylline, metronidazole and nifedipine.